Resumo
Diagnósticos diferenciais
comuns
- Alcohol induced
- Steatotic liver disease
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis
- Hemochromatosis
- Hodgkin lymphoma
- Non-Hodgkin lymphoma (NHL)
- Waldenström macroglobulinemia or lymphoplasmacytic lymphoma
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Acute lymphoblastic leukemia (ALL)
- Chronic lymphocytic leukemia (CLL)
- Hairy cell leukemia
- Myelofibrosis
- Polycythemia vera
- Essential thrombocytosis
- Splenic metastases
- Autoimmune hemolytic anemia
- Rheumatoid arthritis (RA)
- Felty syndrome
- Systemic lupus erythematosus
- Sarcoidosis
- Malaria
- Epstein-Barr virus (EBV)
- Endocarditis
- Sepsis-related splenic abscesses
- Chronic hepatitis C
- Chronic hepatitis B
- Sickle cell anemia
- Cytoskeletal defects
- Thalassemias
Incomuns
- Benign splenic tumors
- Portal vein thrombosis
- Splenic vein thrombosis
- Budd-Chiari syndrome
- Hemophagocytic lymphohistiocytosis (HLH)
- Amyloidosis
- Gaucher or Niemann-Pick disease
- Severe dengue
- Splenic rupture
- Subcapsular hemorrhage
- Secondary to granulocyte colony-stimulating factor (G-CSF)
Colaboradores
Autores
Terri L. Parker, MD
Assistant Professor of Medicine
Section of Hematology
Yale School of Medicine
Smilow Cancer Center at Yale-New Haven
New Haven
CT
Declarações
TLP declares that she has no competing interests.
Agradecimentos
Dr Terri L. Parker would like to gratefully acknowledge Dr Alan E. Lichtin, the previous contributor to this monograph.
Declarações
AEL has received research support from Amgen.
Revisores
Priyanka Mehta, MD
Consultant Haematologist
Bristol Haematology and Oncology Centre
Bristol
UK
Declarações
PM declares that she has no competing interests.
Ruben A. Mesa, MD
Professor of Medicine
Mayo Clinic
Scottsdale
AZ
Declarações
RAM declares that he has no competing interests.
Giovanni Barosi, MD
Director of the Laboratory of Clinical Epidemiology
IRCCS Policlinico S. Matteo Foundation
Pavia
Italy
Declarações
GB declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referências
Principais artigos
Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023 Oct;82(10):1271-85.Texto completo Resumo
Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-58.Texto completo Resumo
Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Folhetos informativos para os pacientes
Hepatitis B: should I have the vaccine?
Hepatitis C: what is it?
Mais Folhetos informativos para os pacientesConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal